Physician profile
Raymond Cheng
NPI 1649345398
$39,689.99
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $14K · 2021: $362.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19,065.18 | 2019-2020 | |
| Greenwich Biosciences, INC. | $10,215.07 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $5,738.46 | 2019-2020 | |
| Ucb Sa | $2,160.00 | 2020 | |
| Ucb, INC. | $473.54 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $340.17 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $256.09 | 2019-2020 | |
| Tris Pharma INC | $210.87 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $170.29 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $159.62 | 2019-2020 | |
| Neos Therapeutics, LP | $158.18 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $116.48 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $110.05 | 2019-2020 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $87.78 | 2019 | |
| Sk Life Science, INC. | $85.68 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $51.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.19 | 2020 | |
| Shire North American Group INC | $49.09 | 2019 | |
| Adlon Therapeutics L.P. | $47.90 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $36.63 | 2019-2020 | |
| Neurelis, INC. | $31.53 | 2020 | |
| Livanova USA, INC. | $31.13 | 2020 | |
| Natus Medical Incorporated | $26.79 | 2020 | |
| Alexion Pharmaceuticals, INC. | $11.93 | 2019 | |
| Travere Therapeutics, INC. | $5.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.